Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

AV Nodal Ablation With Conduction System Pacing Versus Cardiac Resynchronization for Symptomatic Heart Failure Patients With Atrial Fibrillation (APAF-CSP)

19. maj 2026 opdateret af: M. Rienstra, University Medical Center Groningen

AV Nodal Ablation With Conduction System Pacing Versus Cardiac Resynchronization for Symptomatic Heart Failure Patients With Atrial Fibrillation: The APAF-CSP All-cause Mortality and Quality of Life Trial

The goal of this clinical trial is to learn if conduction system pacing works as well as cardiac resynchronization therapy (CRT) post atrioventricular (AV) node ablation in adult patients with symptomatic heart failure and atrial fibrillation that is not suitable for rhythm control.

The main question it aims to answer is:

Is AV node ablation with conduction system pacing noninferior to AV node ablation with CRT for the hierarchical composite outcome of all-cause mortality, heart failure hospitalization or urgent heart failure visit, and meaningful improvement in heart failure-related quality of life?

Participants will undergo:

  • An AV node ablation and be randomly assigned to receive either a conduction system pacing or a CRT.
  • Attend follow-up visits (in clinic or by telephone) at baseline, intervention day, 3-month, 12-month, 24-month, and 36-month after the procedure.
  • Complete questionnaires about heart failure symptoms and quality of life at baseline, 12 months, and yearly.
  • Have an echocardiogram, an electrocardiogram, and blood tests at baseline and 1 year
  • At selected centers: they will be asked to wear a bracelet that measures arterial stiffness for 30 minutes and provide a urine sample at baseline and 1 year.

Studieoversigt

Status

Ikke rekrutterer endnu

Betingelser

Intervention / Behandling

Detaljeret beskrivelse

  • Study Rationale:

Therapeutic options for patients with symptomatic HF and AF that is not suitable for rhythm control are limited to pharmacological rate control and/or AV node ablation plus CRT implantation (Class IIa, Level of Evidence B). CSP is gaining more and more attention, and it has the advantage of utilizing the native conduction system to activate both ventricles simultaneously. This would achieve more physiologically synchronized ventricular contraction and circulation dynamics. We hypothesize that conduction system pacing would be as efficient as CRT pacing in patients with symptomatic heart failure and AF that is not suitable for rhythm control who are receiving the "ablate and pace" treatment strategy.

+Objective:

  1. Primary Objective:

    To compare AV node ablation with conduction system pacing versus AV node ablation with cardiac resynchronization therapy (CRT) among the trial population with respect to the hierarchical composite endpoint of all-cause mortality, HF hospitalization or unplanned/urgent HF visit, and ≥5 point improvement (increase) in the Kansas City Cardiomyopathy Questionnaire (KCCQ) score.

  2. Secondary Objectives:

    To determine the effect of AV node ablation with conduction system pacing compared to AV node ablation with cardiac resynchronization therapy (CRT) among the trial population in the following outcomes:

    -≥5 point improvement (increase) in the Kansas City Cardiomyopathy Questionnaire (KCCQ) score.

    • Quality of life measures (EQ-5D and AFEQT questionnaires). -HF hospitalization or unplanned/urgent HF visit. -Cardiovascular related hospitalization. -All-cause mortality. -Cardiovascular related mortality. Tertiary (Exploratory) Objectives: To determine the effect of AV node ablation with conduction system pacing compared to AV node ablation with cardiac resynchronization therapy (CRT) among the trial population in the following outcomes:
    • Duration of hospitalization for cardiovascular causes
    • Worsening heart failure (NYHA class at baseline,1 year and at end of follow-up),
    • Healthcare costs and cost-effectiveness,
    • Trends of NT-proBNP levels at baseline and follow up
    • Change in left ventricular ejection fraction (LVEF) at baseline and 1 year
    • Change in renal function metrics (Glomerular Filtration Rate (GFR), Creatinine (Cr) and blood Urea levels (BUN)) at baseline and 1 year.
    • Change in urine Microalbumin (by urine dipstick) at baseline and 1 year (only in the subgroup analysis).
    • Change in measured arterial stiffness index measured by the photoplethysmography (PPG) signals through a non-invasive blood-volume sensing wearable bracelet, at baseline and 1 year (only in the subgroup analysis).
    • Short-term safety outcomes: This includes the composite of short-term (i.e. within 3 months) post procedure related complications (i.e. Cardiac tamponade, Pneumothorax, postoperative wound infection, Pocket hematomas, lead dislodgment, vascular injury, Thromboembolism, and Pericarditis).

    • Long term safety outcomes: This includes the composite of long-term (i.e. within 3 years) post procedure related complications (Device and Lead integrity related complications (i.e. lead dislodgment, lead malfunction, generator malfunction, lead related infections)).

      • Study design:

    The APAF-CSP trial is a prospective, multicenter, international, randomized, open-label, non-inferiority, parallel-arms trial. Patients who have atrial fibrillation (AF), that is not suitable for rhythm control, and a history of at least one hospitalization or unplanned/urgent care visit due to heart failure within the last 2 years, regardless of left ventricular ejection fraction or QRS duration, will be invited to participate. The trial will take place in 23 participating hospitals in Europe (Netherlands, Germany, Italy and France).

    +Study population: Adult patients aged 18 years or older, with confirmed AF that is unsuitable for rhythm control and symptomatic HF (with a history of at least one hospitalization or unplanned/urgent care visit due to HF exacerbation within the 2 years before enrolment), regardless of left ventricular ejection fraction or QRS duration, will be invited to participate in this trial. Based on sample size estimations, the trial needs 292 patients with a median follow-up of 2.5 years.

    +Intervention: All patients meeting the inclusion criteria and not meeting any exclusion criteria will be randomized in a 1:1 ratio to undergo either AV node ablation with CSP or AV node ablation with CRT implantation. Throughout the trial, patients will be followed up at predefined intervals for endpoint data collection.

    +Main study endpoint: The hierarchical primary composite endpoint is the composite of all-cause mortality, HF hospitalization or unplanned/urgent HF visit, and ≥5 point improvement (increase) in the Kansas City Cardiomyopathy Questionnaire (KCCQ).

    +Nature and extent of the burden and risks associated with participation, benefit and group relatedness: AV node catheter ablation and pacemaker implantation, whether CRT or CSP, are well-established and safe techniques. They are well-known for their efficiency for rate control in the appropriate population. The follow-up assessments will be conducted either physically (i.e. patient visits) and/or (when possible) remotely (i.e. telephone encounter) to minimize patient effort. Additional study procedures, such as transthoracic echocardiography and blood sample collection, will be performed at baseline during the screening assessment and during the 1-year follow-up visit. These procedures are part of usual clinical care for these patients undergoing AV nodal ablation with pacemaker implantation. Consequently, the additional effort and time to fill out a few "Quality-of-Life" questionnaires are determined to be the main extra burden that consumes time for both the patient and the treating physician. However, this increased burden is non-invasive and will be highlighted in the consent/participation form. In pre-selected centers (subgroup analyses), a urine sample for the microalbumin check will be collected at baseline and the 1-year visit. Furthermore, the vascular stiffness index (VSI) will be measured by a wearable bracelet. This VSI measurement will be performed at the baseline visit and at the 1-year follow up visit, where the participant will be asked to wear the device for 30 minutes (during the visit). The VSI recording and urine microalbumin check are painless, non-invasive and fully funded by the study. The patient will not be required to come for an extra visit to the study site for the sole reason of this recording or for the urine sample, and instead, this is incorporated into the scheduled study visits. However, the increased burden of providing a urine sample and wearing the bracelet during the visit is fully acknowledged and will be highlighted in the consent/participation forms.

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

292

Fase

  • Ikke anvendelig

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

  • Navn: Michiel Rienstra, MD, PhD, MHA, Professor
  • Telefonnummer: +31503611327
  • E-mail: m.rienstra@umcg.nl

Undersøgelse Kontakt Backup

Studiesteder

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

  • Voksen
  • Ældre voksen

Tager imod sunde frivillige

Ingen

Beskrivelse

Inclusion Criteria:

  • Age 18 years or above.
  • Patient is diagnosed with AF and deemed not amenable to rhythm control. This diagnosis of AF will be demonstrated by at least one Electrocardiograph (ECG) showing AF that was performed within one year prior to enrollment.
  • Has history of stable heart failure (regardless left ventricular ejection fraction) and has a history of at least one HF related hospitalization or emergency room/urgent care visit within 2 years prior to enrollment, despite being on maximally tolerable guideline directed medical therapy.
  • Willing and capable to provide informed consent.

Exclusion Criteria:

  • NYHA functional class IV.
  • Severe concomitant non-cardiac disease.
  • Patient who require any cardiac surgical intervention.
  • Previously implanted pacing devices (pacemaker/ICD/CRT) with ≥40% pacing burden.

  • Any of the following within the 3 months prior to enrollment:

    • Myocardial infarction
    • Unstable angina
    • Percutaneous coronary intervention
    • Stroke or TIA
    • Significant bleeding
    • Pericarditis/effusions
  • Coronary artery bypass surgery/atriotomy within 6 months prior to enrolment.
  • Women who are pregnant or breastfeeding.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Andet: CSP Group (Intervention Group)
AV node ablation plus Conduction System Pacing implantation. CSP is established pacing strategy evaluated in comparison with CRT.
Procedure: Conduction System Pacing
The implantation of a pacing device with a pacing lead that aims to capture and pace the native conduction system.
Aktiv komparator: CRT Group (Control Group)
AV node ablation plus cardiac resynchronization therapy implantation. CRT is established standard pacing strategy.
Procedure: Cardiac resynchronization therapy
The implantation of a pacing device with a pacing leads that aims to capture and pace both ventricles in a synchronized fashion, to achieve the best possible hemodynamic parameters and synchrony.

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
The hierarchical composite endpoint of all-cause mortality, HF hospitalization or unplanned/urgent HF visit, and ≥5 point improvement (increase) in the Kansas City Cardiomyopathy Questionnaire (KCCQ) score.
Tidsramme: From enrollment to the end of follow up (median follow-up of 2.5 years)
The Kansas City Cardiomyopathy Questionnaire (KCCQ) scores are scaled 0-100 (the higher score indicates a better condition).
From enrollment to the end of follow up (median follow-up of 2.5 years)

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Major secondary endpoint: ≥5 point improvement (increase) in the Kansas City Cardiomyopathy Questionnaire (KCCQ) score.
Tidsramme: From enrollment to the end of follow up (median follow-up of 2.5 years)
The Kansas City Cardiomyopathy Questionnaire (KCCQ) scores are scaled 0-100 (the higher score indicates a better condition).
From enrollment to the end of follow up (median follow-up of 2.5 years)
Quality of Life Improvement (AFEQT Questionnaire)
Tidsramme: From enrollment to the end of follow up (median follow-up of 2.5 years)
The AFEQT is a disease-specific questionnaire that focuses on assessing the impact of AF on a person's QoL. It covers several domains, including symptoms, daily activities, treatment concerns, and treatment satisfaction. The AFEQT provides scores for each domain as well as a total score, allowing for a comprehensive evaluation of the specific aspects affected by AF on an individual's QoL. Scale 0-100, higher scores indicate no limitation or disability.
From enrollment to the end of follow up (median follow-up of 2.5 years)
Quality of Life Improvement (EQ-5D-5L Questionnaire)
Tidsramme: From enrollment to the end of follow up (median follow-up of 2.5 years)
The EQ-5D-5L is a questionnaire used to assess health-related QoL across five dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has five response levels indicating the level of problems experienced by the individual ( 1= no problems, 2= slight problems, 3= moderate problems, 4= severe problems, and 5= extreme problems). The EQ-5D-5L also generates a summary index score that represents overall health status based on societal preferences for different health states.
From enrollment to the end of follow up (median follow-up of 2.5 years)
HF Hospitalization or Unplanned/urgent HF Visit
Tidsramme: From enrollment to the end of follow up (median follow-up of 2.5 years)
From enrollment to the end of follow up (median follow-up of 2.5 years)
Cardiovascular Related Hospitalization
Tidsramme: From enrollment to the end of follow up (median follow-up of 2.5 years)
From enrollment to the end of follow up (median follow-up of 2.5 years)
All-cause Mortality
Tidsramme: From enrollment to the end of follow up (median follow-up of 2.5 years)
From enrollment to the end of follow up (median follow-up of 2.5 years)
Cardiovascular Related Mortality
Tidsramme: From enrollment to the end of follow up (median follow-up of 2.5 years)
From enrollment to the end of follow up (median follow-up of 2.5 years)

Andre resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Duration of hospitalization for cardiovascular causes
Tidsramme: From enrollment to the end of follow up (median follow-up of 2.5 years)
Tertiary (Exploratory) Endpoint
From enrollment to the end of follow up (median follow-up of 2.5 years)
Clinical heart failure status (New York Heart Association (NYHA) Functional Classification)
Tidsramme: At baseline,1-year, and at end of follow-up (median of 2.5 years follow-up).

Tertiary (Exploratory) Endpoint.

NYHA Classification (scale I-IV):

Class I: No limitation of physical activity. Class II: Slight limitation of physical activity. Class III: Marked limitation of physical activity. Class IV: Unable to carry on any physical activity without discomfort. Symptoms of heart failure at rest.
At baseline,1-year, and at end of follow-up (median of 2.5 years follow-up).
Healthcare costs and cost-effectiveness parameters
Tidsramme: At the end of follow up (Median of 2.5 years follow up)
Tertiary (Exploratory) Endpoint
At the end of follow up (Median of 2.5 years follow up)
NT-proBNP levels
Tidsramme: At baseline and 1-year follow up.
Tertiary (Exploratory) Endpoint
At baseline and 1-year follow up.
Left ventricular ejection fraction (LVEF)
Tidsramme: At baseline and 1-year follow up.
Tertiary (Exploratory) Endpoint
At baseline and 1-year follow up.
Glomerular Filtration Rate (GFR)
Tidsramme: At baseline and 1-year follow up.
Tertiary (Exploratory) Endpoint
At baseline and 1-year follow up.
Creatinine (Cr) level
Tidsramme: At baseline and 1-year follow up.
Tertiary (Exploratory) Endpoint
At baseline and 1-year follow up.
Blood Urea level (BUN)
Tidsramme: At baseline and 1-year follow up.
Tertiary (Exploratory) Endpoint
At baseline and 1-year follow up.
Urine Microalbumin levels (Only in the subgroup analysis in selected centers)
Tidsramme: At baseline and 1-year follow up.
Tertiary (Exploratory) Endpoint
At baseline and 1-year follow up.
Arterial stiffness index measured by the photoplethysmography (PPG) signals (Only in the subgroup analysis in selected centers).
Tidsramme: At baseline and 1-year follow up.
Tertiary (Exploratory) Endpoint
At baseline and 1-year follow up.
Short-term safety endpoints
Tidsramme: Within 3 months post the procedure
Tertiary (Exploratory) Endpoints. These includes the short-term (i.e. within 3 months) post procedure related complications (i.e. Cardiac tamponade, Pneumothorax, postoperative wound infection, Pocket hematomas, lead dislodgment, vascular injury, Thromboembolism, and Pericarditis)
Within 3 months post the procedure
Long term safety endpoints
Tidsramme: Within 3 years post the procedure
Tertiary (Exploratory) Endpoints. These includes the long-term (i.e. within 3 years) post procedure related complications (Device and Lead integrity related complications (i.e. lead dislodgment, lead malfunction, generator malfunction, lead related infections)).
Within 3 years post the procedure

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

University Medical Center Groningen

Efterforskere

  • Studiestol: Michiel Rienstra, MD, PhD, MHA, Professor, University Medical Center Groningen, Groningen, The Netherlands
  • Ledende efterforsker: Yuri Blaauw, MD, PhD, University Medical Center Groningen

Publikationer og nyttige links

Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.

Generelle publikationer

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Anslået)

1. juli 2026

Primær færdiggørelse (Anslået)

1. juni 2030

Studieafslutning (Anslået)

1. juni 2030

Datoer for studieregistrering

Først indsendt

12. maj 2026

Først indsendt, der opfyldte QC-kriterier

19. maj 2026

Først opslået (Faktiske)

22. maj 2026

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

22. maj 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

19. maj 2026

Sidst verificeret

1. maj 2026

Mere information

Begreber relateret til denne undersøgelse

Nøgleord

Yderligere relevante MeSH-vilkår

Andre undersøgelses-id-numre

  • NL-011147

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

JA

IPD-deling Understøttende informationstype

  • STUDY_PROTOCOL
  • SAP
  • ICF
  • ANALYTIC_CODE
  • CSR

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Kliniske forsøg med Hjertefejl

Kliniske forsøg med Conduction System Pacing

Søg i lignende forsøg

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

CROs by country

CROs in Turkmenistan

Betingelser

Sjældne sygdomme

Narkotikainterventioner

Kosttilskud

Sponsor / samarbejdspartnere

Placeringer

Abonner